Superstring Capital Management
Latest statistics and disclosures from Superstring Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are COGT, AXSM, GMAB, CLDX, TRVI, and represent 37.12% of Superstring Capital Management's stock portfolio.
- Added to shares of these 10 stocks: AXSM (+$11M), RVMD (+$9.6M), GMAB (+$6.4M), TRVI (+$5.1M), COGT, CLYM, CLDX, ONC, ORIC, ANL.
- Started 8 new stock positions in BOLD, ONC, HELP, KNSA, VYNE, RVMD, ROIV, FTH.
- Reduced shares in these 10 stocks: SMMT (-$17M), DFTX (-$7.7M), URGN (-$7.2M), IMVT (-$5.8M), , IQV, SVRA, SION, ARVN, ORKA.
- Sold out of its positions in ARVN, IPSC, CGEM, IQV, ORKA, PTN, PFE, SMMT, TSHA, TVTX. VRTX.
- Superstring Capital Management was a net seller of stock by $-16M.
- Superstring Capital Management has $158M in assets under management (AUM), dropping by 13.15%.
- Central Index Key (CIK): 0001931118
Tip: Access up to 7 years of quarterly data
Positions held by Superstring Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Superstring Capital Management
Superstring Capital Management holds 32 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cogent Biosciences (COGT) | 8.4 | $13M | +52% | 343k | 38.70 |
|
| Axsome Therapeutics (AXSM) | 8.3 | $13M | +380% | 54k | 244.77 |
|
| Genmab A/s Sponsored Ads (GMAB) | 7.5 | $12M | +118% | 431k | 27.47 |
|
| Celldex Therapeutics Com New (CLDX) | 6.8 | $11M | +59% | 288k | 37.21 |
|
| Trevi Therapeutics (TRVI) | 6.2 | $9.8M | +108% | 524k | 18.65 |
|
| Revolution Medicines (RVMD) | 6.0 | $9.6M | NEW | 51k | 187.28 |
|
| Definium Therapeutics Com Shs (DFTX) | 5.6 | $8.9M | -46% | 188k | 47.04 |
|
| Vir Biotechnology (VIR) | 5.5 | $8.7M | +16% | 854k | 10.19 |
|
| Immunovant (IMVT) | 5.1 | $8.0M | -41% | 208k | 38.53 |
|
| Urogen Pharma (URGN) | 4.4 | $7.0M | -50% | 191k | 36.80 |
|
| Eliem Therapeutics (CLYM) | 4.3 | $6.8M | +161% | 521k | 13.04 |
|
| Adlai Nortye Sponsored Ads (ANL) | 4.0 | $6.4M | +33% | 553k | 11.50 |
|
| Savara (SVRA) | 3.8 | $6.0M | -38% | 978k | 6.16 |
|
| Maplight Therapeutics (MPLT) | 2.8 | $4.5M | -34% | 125k | 35.84 |
|
| Oric Pharmaceuticals (ORIC) | 2.8 | $4.4M | +252% | 406k | 10.83 |
|
| United Therapeutics Corporation (UTHR) | 2.5 | $3.9M | +38% | 7.2k | 541.83 |
|
| Vaxcyte (PCVX) | 2.5 | $3.9M | -39% | 67k | 58.13 |
|
| Beone Medicines Sponsored Ads (ONC) | 2.2 | $3.5M | NEW | 12k | 284.97 |
|
| Cabaletta Bio (CABA) | 2.2 | $3.5M | +19% | 1.3M | 2.72 |
|
| Zai Lab Adr (ZLAB) | 1.9 | $3.0M | -43% | 156k | 19.00 |
|
| Sionna Therapeutics (SION) | 1.8 | $2.8M | -55% | 63k | 43.99 |
|
| Bright Minds Biosciences Com New (DRUG) | 1.3 | $2.1M | +128% | 31k | 70.20 |
|
| Aclaris Therapeutics (ACRS) | 0.9 | $1.4M | -29% | 258k | 5.29 |
|
| Cybin Com New (HELP) | 0.9 | $1.4M | NEW | 204k | 6.61 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.8 | $1.2M | NEW | 19k | 63.95 |
|
| Roivant Sciences SHS (ROIV) | 0.6 | $907k | NEW | 26k | 35.39 |
|
| Tonix Pharmaceuticals Hldg C Com New (TNXP) | 0.5 | $812k | 64k | 12.76 |
|
|
| Protara Therapeutics Com Stk (TARA) | 0.3 | $464k | 122k | 3.82 |
|
|
| Faeth Therapeutics Com New (FTH) | 0.2 | $354k | NEW | 14k | 25.00 |
|
| Boundless Bio (BOLD) | 0.1 | $138k | NEW | 55k | 2.50 |
|
| Biomea Fusion (BMEA) | 0.1 | $85k | 250k | 0.34 |
|
|
| Vyne Therapeutics (VYNE) | 0.0 | $40k | NEW | 61k | 0.65 |
|
Past Filings by Superstring Capital Management
SEC 13F filings are viewable for Superstring Capital Management going back to 2023
- Superstring Capital Management 2026 Q2 filed Aug. 14, 2026
- Superstring Capital Management 2026 Q1 filed May 14, 2026
- Superstring Capital Management 2025 Q4 filed Feb. 17, 2026
- Superstring Capital Management 2025 Q3 filed Nov. 14, 2025
- Superstring Capital Management 2025 Q2 filed Aug. 14, 2025
- Superstring Capital Management 2025 Q1 filed May 15, 2025
- Superstring Capital Management 2024 Q4 filed Feb. 14, 2025
- Superstring Capital Management 2024 Q3 filed Nov. 14, 2024
- Superstring Capital Management 2024 Q2 filed Aug. 14, 2024
- Superstring Capital Management 2024 Q1 filed May 15, 2024
- Superstring Capital Management 2023 Q4 filed Feb. 14, 2024